The Alliance of Specialty Medicine filed comments with the Department of Health and Human Services (HHS) on an Advance Notice of Proposed Rulemaking (ANPRM) outlining the Administration’s plans for a mandatory demonstration project related to Medicare Part B drugs. The Alliance expressed its concerns over the scope and mandatory nature of the demo. Additionally, the Alliance noted that the demo, as currently conceptualized, would lead to increased complexity in drug acquisition and shift costs to physicians in Part B.

Click Here to Access the Letter.  


The Alliance Staff

Author The Alliance Staff

More posts by The Alliance Staff

Leave a Reply